{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shang S"],"funding":["Supported by the Research Program of Wuhan Municipal Health and Family Planning Commission"],"pagination":["3000605241233166"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924567"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["52(3)"],"pubmed_abstract":["<h4>Objective</h4>To investigate the correlations between multigene alterations and clinicopathological features in papillary thyroid carcinoma (PTC) samples.<h4>Methods</h4>In this retrospective study, 111 cytological specimens of thyroid nodules, including 74 PTC samples and 37 benign samples, were analyzed using a 22-gene mutation assay employing next-generation sequencing. Clinicopathological information was retrospectively collected and analyzed.<h4>Results</h4>Gene alterations were associated with a higher rate of lymph node metastasis (LNM) and thyroid capsular invasion, a lower rate of coexisting Hashimoto's thyroiditis, the classical PTC subtype, and younger age (<45 years). Among the 22 genes tested, the <i>BRAF</i> mutation rates showed a significant difference between the PTC and benign groups. In the subgroup analysis, younger age (odds ratio = 12.512, 95% confidence interval: 3.126-50.087) was an independent risk factor for LNM. In further analyses, <i>BRAF</i> mutation was significantly associated with LNM in the older subgroup (age ≥ 45 years), suggesting that the <i>BRAF</i> mutation test has greater value for determining PTC prognosis in the older age group.<h4>Conclusions</h4>Our findings will provide a more comprehensive understanding of the relationship between gene mutations and PTC and may contribute to improved PTC management."],"journal":["The Journal of international medical research"],"pubmed_title":["Correlation between genetic alterations and clinicopathological features of papillary thyroid carcinomas."],"pmcid":["PMC10924567"],"funding_grant_id":["[WH21Z40]"],"pubmed_authors":["Yang H","Feng N","Liu H","Wu J","Li X","Zheng Z","Chen M","Zhang Y","Shi X","Shang S"],"additional_accession":[]},"is_claimable":false,"name":"Correlation between genetic alterations and clinicopathological features of papillary thyroid carcinomas.","description":"<h4>Objective</h4>To investigate the correlations between multigene alterations and clinicopathological features in papillary thyroid carcinoma (PTC) samples.<h4>Methods</h4>In this retrospective study, 111 cytological specimens of thyroid nodules, including 74 PTC samples and 37 benign samples, were analyzed using a 22-gene mutation assay employing next-generation sequencing. Clinicopathological information was retrospectively collected and analyzed.<h4>Results</h4>Gene alterations were associated with a higher rate of lymph node metastasis (LNM) and thyroid capsular invasion, a lower rate of coexisting Hashimoto's thyroiditis, the classical PTC subtype, and younger age (<45 years). Among the 22 genes tested, the <i>BRAF</i> mutation rates showed a significant difference between the PTC and benign groups. In the subgroup analysis, younger age (odds ratio = 12.512, 95% confidence interval: 3.126-50.087) was an independent risk factor for LNM. In further analyses, <i>BRAF</i> mutation was significantly associated with LNM in the older subgroup (age ≥ 45 years), suggesting that the <i>BRAF</i> mutation test has greater value for determining PTC prognosis in the older age group.<h4>Conclusions</h4>Our findings will provide a more comprehensive understanding of the relationship between gene mutations and PTC and may contribute to improved PTC management.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-23T03:20:39.746Z","creation":"2025-04-22T00:57:13.769Z"},"accession":"S-EPMC10924567","cross_references":{"pubmed":["38456650"],"doi":["10.1177/03000605241233166"]}}